ARPA-H Awards $3.5 Million Contract to BelleTorus Corp. (Belle.ai) to Expand Pediatric Healthcare Access Using Artificial Intelligence
October 11, 2023 06:12 ET
|
Belle.ai
ARPA-H awards $3.5 million contract to Belle.ai and UHP to develop an AI-driven pediatric telehealth solution for skin, ear, and throat conditions.
Dermatology Lasers Market Thrives on Rising Incidences of Skin Cancer and Aesthetic Treatments
October 02, 2023 06:23 ET
|
Research and Markets
Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Dermatology Lasers Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global dermatology lasers market is on...
Global Dermatology CRO Market 2023-2030: Intellectual Property Challenges Pose Hurdles to Dermatology CRO Industry Growth
September 22, 2023 06:58 ET
|
Research and Markets
Dublin, Sept. 22, 2023 (GLOBE NEWSWIRE) -- The "Dermatology CRO Market Size, Share & Trends Analysis Report By Type (Preclinical, Clinical), By Service Type (Laboratory, Regulatory/Medical...
Phototherapy Equipment Global Market to Reach $473.5 Billion by 2030: Increasing Number of Preterm Births to Drive the Adoption of Phototherapy Equipment
March 31, 2023 09:38 ET
|
Research and Markets
Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "Phototherapy Equipment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Dermatology Devices Global Market Report 2023: Increasing Prevalence of Skin Cancer and Other Conditions Fuels Demand
March 24, 2023 07:08 ET
|
Research and Markets
Dublin, March 24, 2023 (GLOBE NEWSWIRE) -- The "Dermatology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global dermatology devices market grew...
Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
February 21, 2023 07:30 ET
|
Palvella Therapeutics
- Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b...
Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023
February 07, 2023 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that it has...
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
January 09, 2023 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a...
Insights on the Canine Atopic Dermatitis Global Market to 2027 - Increasing Occurrence of CAD in Domesticated Dogs Drives Growth
January 06, 2023 06:58 ET
|
Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Canine Atopic Dermatitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Global Photodynamic Therapy Market to 2031 - Featuring Galderma, Bausch Health and Lumenis Among Others
January 04, 2023 04:18 ET
|
Research and Markets
Dublin, Jan. 04, 2023 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Global Market Opportunities And Strategies To 2031: COVID-19 Implications And Growth" report has been added to ...